StartupsQuartzabout 2 hours ago
Johnson & Johnson Funds Psychedelic Startup
2 min read
Johnson & Johnson led a $100 million Series C financing in Delix Therapeutics on Monday. The capital funds Phase II development of zalsupindole, with a trial starting in the first half of 2027 enrolling 240 patients. Data arrives in the first half of 2028. The drug showed a mean reduction of about 50% in depression scores after one week.
Level
Hype check
Tap to vote and see what everyone thinks.
